TY  - JOUR
AU  - Urbanska, Edyta Maria
PY  - 2023
TI  - Choice of first-line anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) based on the results of a systematic review and network meta-analysis
JF  - Precision Cancer Medicine; Vol 6 (June 30, 2023): Precision Cancer Medicine
Y2  - 2023
KW  - 
N2  - 
UR  - https://pcm.amegroups.org/article/view/7703